NEW YORK (AP) — King Pharmaceuticals Inc. and Acura Pharmaceuticals Inc. said Friday they don't expect to have to run new clinical trials of an abuse-resistant pain drug in order to gain Food and Drug Administration approval.
CUPERTINO, Calif. (AP) — Drug developer Durect Corp. said Thursday it signed a long-term agreement...
NEW YORK (AP) — King Pharmaceuticals Inc. and partner Pain Therapeutics Inc. expect to resubmit an...
MARLEY SEAMAN AP Health Writer NEW YORK (AP) — King Pharmaceuticals Inc. in 2008 paid its chief executive a little more than half his compensation from the previous year, largely because of a decline in stock and options awards, according to an Associated Press analysis of a regulatory filing.
BRISTOL, Tenn. (AP) — King Pharmaceuticals Inc. said Thursday it lost almost $550 million in the fourth quarter, largely due to the costs of acquiring rival Alpharma Inc. The company also lost patent protection on its painkiller Altace a year ago, which caused sales to drop.
By MATTHEW PERRONE AP Business Writer WASHINGTON (AP) — Federal health regulators are requiring more than a dozen drugmakers to develop plans to reduce the misuse of their painkillers, which cause hundreds of deaths each year.
NEW YORK (AP) - Acura Pharmaceuticals Inc. will receive a $3 million payment from King Pharmaceuticals under a continuing licensing deal, the companies said Wednesday. Bristol, Tenn.-based King exercised its option to license a fourth immediate-release pain treatment using Palatine, Ill.
NEW YORK (AP) — King Pharmaceuticals Inc. extended its $37-per-share buyout offer for Alpharma Inc. on Monday and has already acquired about 92 percent of the company's outstanding stock. The offer is now extended to 10.a.m. Dec. 29. It was set to expire Dec. 19.Bridgewater, N.J.
NEW YORK (AP) _ Alpharma Inc. has finally agreed to King Pharmaceuticals Inc.'s $1.6 billion cash takeover offer, ending the drugmakers' months-long battle. Last Monday, Bristol, Tenn.
King Pharmaceuticals, Inc. has announced that it is extending its previously announced tender offer for all outstanding shares of Class A Common Stock of Alpharma Inc. until 5:00 pm, New York City time, on November 21, 2008, unless the offer is further extended.
The Board of Directors of Alpharma Inc., a global specialty pharmaceutical company, recently filed
Alpharma Urges Shareholders to Take No Action with Respect to King Pharmaceuticals' Announced Intent to Commence a Tender OfferSeptember 15, 2008 12:54 pm | News | Comments
The Board of Directors of Alpharma Inc., a global specialty pharmaceutical company, has urged shareholders to take no action with respect to the announcement by King Pharmaceuticals, Inc.
King Pharmaceuticals, Inc. recently announced that the FDA has approved the company's new state-of-the-art manufacturing and production facility in Rochester, Michigan for its Bicillin® product line.
WASHINGTON, DC (December 7, 2004) – The Food & Drug Administration (FDA) last week announced labeling changes regarding Bicillin CR (penicillin G benzathine and penicillin G procaine injectable suspension) and Bicillin LA (penicillin G benzathine injectable suspension).
BRISTOL, TN (July 19, 2004) - King Pharmaceuticals, Inc. reported that they have selected Brian A. Markison as King's president and CEO. He has also been elected to the board of directors.
BRISTOL, TN (May 24, 2004) – Jefferson J. Gregory has resigned as chairman and chief executive officer of King Pharmaceuticals, Inc., the company said last week. The company said its board of directors accepted Gregory's resignation, which was effective May 14.